Nivolumab at Micro Doses Works Better than Chemotherapy Against Relapsed Cancer
In Mumbai, India, and other parts of the world, immunotherapy is not always available for every patient who needs it.…
Melanoma Research
06/05/2025
Nivolumab at Micro Doses Works Better than Chemotherapy Against Relapsed Cancer
In Mumbai, India, and other parts of the world, immunotherapy is not always available for every patient who needs it.…
|
06/05/2025
The Time of Day Pembrolizumab is Administered May Link to Patient Survival
Timing matters. A study presented at the annual meeting of the American Society of Clinical Oncology in Chicago suggests that…
|
06/05/2025
Three New Immunotherapy Agents Tested Against Melanoma in Phase 2 Clinical Trials
Several new agents designed to reactivate the immune system were tested in combination with FDA-approved immunotherapies, as reported in data…
|
06/05/2025
Genetic Test a Potential Alternative to Sentinel Lymph Node Biopsy
There may be a non-invasive option available for patients with head and neck melanoma who cannot easily receive a sentinel…
|
06/05/2025
New Therapy in Clinical Trial Returns Immunotherapeutic Activity to Resistant Melanoma
A group in Italy may have found a way to revive the response to immunotherapy in patients who have developed…
|
06/05/2025
Early Clinical Trial Shows Drug Activity to Work in Patients with Acral and Mucosal Melanoma
Results of a Phase 1/2 clinical trial showed promising data for patients with advanced acral and mucosal melanoma. The results…
|
06/05/2025
Results Prove Immunotherapy Should be the Initial Treatment for BRAF Mutant Tumors
Five-year clinical trial results presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago confirmed…
|
06/03/2025
Trial Result Confirms the Advantage of Cemiplimab for Skin Cancer at High Risk of Recurrence
We usually don’t feature nonmelanoma skin cancer articles here, but we thought you might be interested in what’s happening in…
|
05/28/2025
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
News provided byHalozyme Therapeutics, Inc. May 28, 2025, 08:30 ET Opdivo® is the first and only PD-1 inhibitor approved for subcutaneous (SC)…
|
|
05/09/2025
Tri-State Melanoma Consortium – Inaugural Convening
Last night, leading melanoma researchers and clinicians from across the New York , New Jersey, and Connecticut region gathered at…
|
Recent Posts
Jun. 10, 2025
Coping with Cancer: DBT Skills for Emotional Resilience
Jun. 06, 2025
May in Review: A Marathon Month of Melanoma Awareness, Education, and Community
Jun. 06, 2025
AIM at Melanoma’s 4th Annual Evening in Memory of Valerie Guild
Jun. 05, 2025
Nivolumab at Micro Doses Works Better than Chemotherapy Against Relapsed Cancer
Jun. 05, 2025